2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-115912
    GPVI antagonist 3 901654-94-2 98%
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.
    GPVI antagonist 3
  • HY-116042
    FSCPX 156547-56-7 99.72%
    FSCPX is a potent and selective irreversible antagonist of A1 adenosine receptor (A1AR), with low nanomolar potency for binding to the A1AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial adenosine level in the guinea pig atrium.
    FSCPX
  • HY-116050
    17(S)-HETE 183509-25-3 98%
    17S-HETE is arachidonic acid metabolite through cytochrome P-450 pathways. 17S-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy.
    17(S)-HETE
  • HY-116051
    16,16-Dimethylprostaglandin F2α 39746-23-1 98%
    16,16-Dimethylprostaglandin F2α (16,16-Dimethyl-PGF2α) is a potent analog of PGF2α (HY-12956), which exhibits similar binding potency as PGF2α does. 16,16-Dimethylprostaglandin F2α serves as a bronchoconstrictor.
    16,16-Dimethylprostaglandin F2α
  • HY-116119
    BDF 9148 120838-62-2 98%
    BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure.
    BDF 9148
  • HY-116158
    Oosponol 146-04-3 98%
    Oosponol is a dopamine beta-hydroxylase inhibitor exhibiting hypotensive effects.Oospongol has strong antifungal activity against many antagonistic fungi.
    Oosponol
  • HY-116161
    Bimatoprost isopropyl ester 130273-87-9 98%
    15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α isopropyl ester) is the latanoprost-related isomer containing both a double bond at 13,14 and an inverted (β) hydroxyl group at C-15. Similar to 15(S)-latanoprost, 15(R)-17-phenyl trinor PGF2α isopropyl ester is a potential impurity in most commercial preparations of the latanoprost bulk drug product. The IC50 values for the free acid forms of 15(S)-17-phenyl trinor PGF2α and 15(R)-17-phenyl trinor PGF2α were determined to be 0.71 nM and 30 nM, respectively, in a FP receptor binding assay using the cat iris sphincter muscle.1 A 3 μg dose of 15(R)-17-phenyl trinor PGF2α caused a 1.9 mmHg reduction of IOP in normotensive cynomolgus monkeys.
    Bimatoprost isopropyl ester
  • HY-116295
    MRS2690 7077-89-6 98%
    MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease.
    MRS2690
  • HY-116312
    8-pCPT-2′-O-Me-cAMP 510774-50-2 98%
    8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50 >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration.
    8-pCPT-2′-O-Me-cAMP
  • HY-116400
    BN 50341 107550-66-3 98%
    BN 50341 is an orally active anticalcic agent and a benzazepine derivative. BN 50341 decreases the in vivo electrically induced thrombus formation in rat or guinea-pig artery and can be utilized in cardiovascular research.
    BN 50341
  • HY-116431
    I-BOP 128719-90-4 98%
    I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle. I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons.
    I-BOP
  • HY-116457
    Propanidid 1421-14-3 98.19%
    Propanidid (Sombrevin; Fabantol) is a γ-aminobutyric acid type A (GABAA) receptor agonist and a short-acting non-barbiturate general agent that can suppress or relieve pain. Propanidid can decrease the arterial pressure.
    Propanidid
  • HY-116540
    L 858051 110452-75-0 98%
    L 858051 is an analog of Forskolin (HY-15371) that activates adenylate cyclase while also having modulatory effects on intracellular cAMP levels, particularly enhancing the CNG current in cardiac myocytes.
    L 858051
  • HY-116556
    Rilmakalim 132014-21-2 98%
    Rilmakalim (HOE 234) is a potassium channel opener (PCO) that activates ATP-sensitive K+ channels in the heart or other tissues.
    Rilmakalim
  • HY-116569
    VU0455691 1392443-41-2 98%
    VU0455691 is a potent, selective orthosteric M1 mAChR antagonist (pIC50=6.64; IC50=0.23 µM for hM1).
    VU0455691
  • HY-116613
    FR-181877 172936-99-1 98%
    FR-181877 (compound 4) is a non-prostaglandin PGI2 agonist. FR-181877 inhibits ADP (HY-W010918)-induced human platelet aggregation with an IC50 value of 0.081 μM.
    FR-181877
  • HY-116675
    Sulmazole 73384-60-8 98%
    Sulmazole is a cardiotonic agent. Sulmazole has competitive inhibitory for A1 adenosine receptor. Sulmazole can improve cardiac index and reduce pulmonary capillary wedge pressure.
    Sulmazole
  • HY-116678
    Cloricromen 68206-94-0 98%
    Cloricromen (Cloricromene) is a platelet aggregation inhibitor. Cloricromen can inhibit platelet aggregation in man and in experimental thrombosis.
    Cloricromen
  • HY-116757
    (±)-α-CMBHC 7083-09-2 98%
    (±)-α-CMBHC is a metabolite of α-Tocopherol.
    (±)-α-CMBHC
  • HY-116759
    VU0405601 712325-30-9 99.93%
    VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia.
    VU0405601
Cat. No. Product Name / Synonyms Application Reactivity